Talaris CEO departs; CFO Fenton takes interim CEO role; strategic review underway

Tourmaline Bio, Inc.

Scott Requadt left as CEO and President effective May 26, 2023; no disagreement cited.
CFO Mary Kay Fenton appointed interim CEO and President, remaining CFO.
Requadt to receive $50,000/month as strategic advisor through August 26, 2023.
Company conducting strategic review including possible business combination or divestiture.
Workforce reduction previously announced; no timetable set for review.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Mary Kay Fenton

Interim Chief Executive Officer and President

Tourmaline Bio, Inc.

Effective: 2023-05-26
Filed: May 30, 2023, 7:59 PM ET

Effective May 26, 2023, the Board of Directors of the Company (the “ Board ”) appointed Mary Kay Fenton, the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed.

Departed

Scott Requadt

Chief Executive Officer and President

Tourmaline Bio, Inc.

Effective: 2023-05-26
Successor: Mary Kay Fenton
Filed: May 30, 2023, 7:59 PM ET

As previously announced, effective May 26, 2023, Scott Requadt left his role as Chief Executive Officer and President of Talaris Therapeutics, Inc.

Departed

Scott Requadt

Director

Tourmaline Bio, Inc.

Effective: 2023-05-26
Filed: May 30, 2023, 7:59 PM ET

Mr. Requadt notified the Company of his intent to resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary Kay Fenton was appointed as Interim Chief Executive Officer and President at Tourmaline Bio, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

Effective May 26, 2023, the Board of Directors of the Company (the “ Board ”) appointed Mary Kay Fenton, the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Requadt departed as Chief Executive Officer and President at Tourmaline Bio, Inc..

Action: left
Role: Chief Executive Officer and President

Exact text from the filing

As previously announced, effective May 26, 2023, Scott Requadt left his role as Chief Executive Officer and President of Talaris Therapeutics, Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Requadt resigned as Director at Tourmaline Bio, Inc..

Action: resigned
Role: Director

Exact text from the filing

Mr. Requadt notified the Company of his intent to resign from the Board, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-23-024920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.